CoChat
Sign Up
Cited by 776Antiplatelet Therapy and Cardiovascular DiseasesDiabetes, Cardiovascular Risks, and LipoproteinsInflammatory mediators and NSAID effects

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes<subtitle>A Randomized Controlled Trial</subtitle>

Ogawa, Hisao·2008·JAMA
DOI 10.1001/jama.2008.623
Open this paper in CoChat — free account

Abstract

CONTEXT: Previous trials have investigated the effects of low-dose aspirin on primary prevention of cardiovascular events, but not in patients with type 2 diabetes. OBJECTIVE: To examine the efficacy of low-dose aspirin for the primary prevention of atherosclerotic events in patients with type 2 diabetes. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, prospective, randomized, open-label, blinded, end-point trial conducted from December 2002 through April 2008 at 163 institutions throughout Japan, which enrolled 2539 patients with type 2 diabetes without a history of atherosclerotic disease and had a median follow-up of 4.37 years. INTERVENTIONS: Patients were assigned to the low-dose aspirin group (81 or 100 mg per day) or the nonaspirin group. MAIN OUTCOME MEASURES: Primary end points were atherosclerotic events, including fatal or nonfatal ischemic heart disease, fatal or nonfatal stroke, and peripheral arterial disease. Secondary end points included each primary end point and combinations of primary end points as well as death from any cause. RESULTS: A total of 154 atherosclerotic events occurred: 68 in the aspirin group (13.6 per 1000 person-years) and 86 in the nonaspirin group (17.0 per 1000 person-years) (hazard ratio [HR], 0.80; 95% confidence interval [CI], 0.58-1.10; log-rank test, P = .16). The combined end point of fatal coronary events and fatal cerebrovascular events occurred in 1 patient (stroke) in the aspirin group and 10 patients (5 fatal myocardial infarctions and 5 fatal strokes) in the nonaspirin group (HR, 0.10; 95% CI, 0.01-0.79; P = .0037). A total of 34 patients in the aspirin group and 38 patients in the nonaspirin group died from any cause (HR, 0.90; 95% CI, 0.57-1.14; log-rank test, P = .67). The composite of hemorrhagic stroke and significant gastrointestinal bleeding was not significantly different between the aspirin and nonaspirin groups. CONCLUSION: In this study of patients with type 2 diabetes, low-dose aspirin as primary prevention did not reduce the risk of cardiovascular events. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00110448.

Overview

Integrity signals

Registry

Crossref · 10.1001/jama.2008.623

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 32 references

Cited by

Sorted by citations

Items 301–400 of 776

Related

See all

Metadata

Authors
Ogawa, H.
Affiliations
Kumamoto University (JP)
Corresponding author
Ogawa, Hisao
ORCID
Ogawa, Hisao
Venue
JAMA
Publisher
American Medical Association (AMA)
Published
2008-11-12
Volume
300
Issue
18
Pages
2134
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
DOI
10.1001/jama.2008.623
OpenAlex
W2050820265
Cited by
776
References
32
Citations by year
2026: 7 · 2025: 11 · 2024: 13 · 2023: 18 · 2022: 27 · 2021: 30 · 2020: 28 · 2019: 67 · 2018: 37 · 2017: 32 · 2016: 48 · 2015: 39 · 2014: 54 · 2013: 50 · 2012: 70
FWCI
58.92
Type
journal article
Language
en
Open access
closed
Locations
  • JAMA (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
Keywords
low-dose aspirin, type 2 diabetes, primary prevention, atherosclerotic events, cardiovascular disease, myocardial infarction, stroke, peripheral arterial disease, hemorrhagic stroke, gastrointestinal bleeding, bleeding risk, mortality, cardiovascular risk reduction, antiplatelet therapy, statins, ACE inhibitors, beta-blockers, antihypertensive drugs, cardiovascular risk stratification
MeSH terms
Adult, Aged, Aged, 80 and over, Aspirin, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Double-Blind Method, Female, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review